Blog
RSS FeedPosted by Michael Wonder on 30 Oct 2018
Analysis of base-case ICERs accepted by the PBAC (July 2018)
30 October 2018 - There appear to be one or two examples where the PBAC accepted a higher than usual ...
Posted by Michael Wonder on 30 Oct 2018
Proposal to change how discarded medicines are reimbursed
30 October 2018 - PHARMAC is seeking feedback on a proposal to change how the agency reimburses discarded medicines in ...
Posted by Michael Wonder on 29 Oct 2018
Mavenclad (cladribine tablets) receives positive CADTH Canadian Drug Expert Committee recommendation
29 October 2018 - Funding recommendation marks an important step to provide access to this innovative new oral treatment for Canadians ...
Posted by Michael Wonder on 29 Oct 2018
NICE turns down hyperkalaemia therapies
29 October 2018 - Preliminary guidelines released by the NICE do not recommend NHS funding for hyperkalaemia treatments Lokelma and ...
Posted by Michael Wonder on 29 Oct 2018
Is 'lowest cost alternative' rapidly becoming the most common main comparator accepted by the PBAC?
29 October 2018 - Further analysis of the first round of Public Summary Documents from the July 2018 PBAC meeting ...
Posted by Michael Wonder on 28 Oct 2018
Is the PBAC's stance on the choice of the main comparator changing?
29 October 2018 - Analysis of the first round of Public Summary Documents from the July 2018 PBAC meeting reveals ...
Posted by Michael Wonder on 28 Oct 2018
Update on proposal to move to one funded brand of lamotrigine (Logem)
26 October 2018 - PHARMAC would like to thank everyone who provided feedback on a proposal to move to one ...
Posted by Michael Wonder on 28 Oct 2018
Calls for PHARMAC review after funds made available to offset wage settlements
24 October 2018 - A request that the government's drug-buying agency be reviewed has opposition support with claims money is ...
Posted by Michael Wonder on 28 Oct 2018
PBAC Public Summary Documents - July 2018 meeting
26 October 2018 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the July 2018 PBAC ...
Posted by Michael Wonder on 28 Oct 2018
Potent drugs to treat lung cancer and high cholesterol added to PBS
28 October 2018 - Australians with advanced lung cancer and a genetic high-cholesterol condition will have cheaper access to potent ...
Posted by Michael Wonder on 26 Oct 2018
AbbVie’s CLL drug Venclyxto too expensive for NHS, says NICE
26 October 2018 - NICE has said AbbVie’s Venclyxto (venetoclax), in combination with development partner Roche’s MabThera/Rituxan (rituximab), is not ...
Posted by Michael Wonder on 25 Oct 2018
States threaten hospital funding war over $600m 'recalculation'
25 October 2018 - A dispute between the Commonwealth and the states and territories over health funding has reached critical ...
Posted by Michael Wonder on 25 Oct 2018
Price of medicinal cannabis halves, but still too expensive for many
26 October 2018 - The cost of medicinal cannabis has halved over the past year, but Australian patients are still ...
Posted by Michael Wonder on 25 Oct 2018
Review PHARMAC model, urge breast cancer petitioners
25 October 2018 - A group of women battling terminal cancer tell the Herald what they would do with extra time. ...
Posted by Michael Wonder on 24 Oct 2018
Systematic reviews of economic evaluations in health technology assessment: a review of characteristics and applied methods
22 October 2018 - When making decisions in health care, it is essential to consider economic evidence about an intervention. ...